A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Versus Placebo in Patients With Moderate-to-Severe Genital Psoriasis
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 08 Jul 2017
At a glance
- Drugs Ixekizumab (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms IXORA-Q
- Sponsors Eli Lilly
- 05 Dec 2016 Status changed from recruiting to active, no longer recruiting.
- 10 Nov 2016 Planned End Date changed from 1 Jan 2018 to 1 Feb 2018.
- 10 Nov 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Feb 2017.